Autoimmunity and inflammation in status epilepticus: From concepts to therapies

Expert Review of Neurotherapeutics

Volumn 14, Issue 10, 2014, Pages 1181-1202

  Holzer, Franz Josef ^a   Seeck, Margitta ^a   Korff, Christian M ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Autoimmune; Chronic epilepsy; FIRES; GABA; GAD; Hashimoto encephalitis; NMDA; Status epilepticus; VGKC

Indexed keywords

ACICLOVIR; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETIRACETAM; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; PENTOBARBITAL; PHENOBARBITAL; PHENYTOIN; PREDNISOLONE; PROPOFOL; RITUXIMAB; VALPROIC ACID; AUTOANTIBODY;

ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNITY; EPILEPTIC STATE; HUMAN; IMMUNOMODULATION; INFLAMMATION; INTENSIVE CARE UNIT; NONHUMAN; PLASMAPHERESIS; REVIEW; ADULT; AGE; ANIMAL; CHILD; IMMUNOLOGY; PATHOPHYSIOLOGY; RESEARCH; STATUS EPILEPTICUS; TIME;

ADULT; AGE FACTORS; ANIMALS; AUTOANTIBODIES; AUTOIMMUNITY; CHILD; HUMANS; INFLAMMATION; RESEARCH; STATUS EPILEPTICUS; TIME FACTORS;

EID: 84907434905     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2014.956457     Document Type: Review

References (119)

1. Delezenne C. Serum névrotoxique. Annales de l'Institut Pasteur 1900;14:686-905
2. Delezenne C. Pathologie expérimentale et physiologie pathologique. In: Delezenne C, editor. Titres et Travaux Scientifiques. Imprimerie de la Cour d'Appel; Paris: 1912. p. 70-2
3. Jankovic BD, Isakovic K, Horvat J. Partial inhibition of antibody formation by means of anti-ribonucleoprotein serum. Nature 1961;190:1218-19
4. Jankovic BD, Draskoci M, Isakovic K. Antibody response in rabbits following injection of sheep erythrocytes into lateral ventricle of brain. Nature 1961;191:288-9
5. Jankovic BD. From immunoneurology to immunopsychiatry: neuromodulating activity of anti-brain antibodies. Int Rev Neurobiol 1985;26:249-314
6. Vezzani A, Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 2005;46(11):1724-43
7. Vezzani A. Epilepsy and inflammation in the brain: overview and pathophysiology. Epilepsy Curr 2014;14(1):3-7
8. Vezzani A, Ruegg S. The pivotal role of immunity and inflammatory processes in epilepsy is increasingly recognized: introduction. Epilepsia 2011;52(Suppl 3): 1-4
9. Fabene PF, Navarro Mora G, Martinello M, et al. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat Med 2008;14(12):1377-83
10. Tomkins O, Shelef I, Kaizerman I, et al. Blood-brain barrier disruption in post-traumatic epilepsy. J Neurol Neurosurg Psychiatry 2008;79(7):774-7
11. Korn A, Golan H, Melamed I, et al. Focal cortical dysfunction and blood-brain barrier disruption in patients with Postconcussion syndrome. J Clin Neurophysiol 2005;22(1): 1-9
12. Janigro D, Iffland PH, et al. Marchi N, Granata T. A role for inflammation in status epilepticus is revealed by a review of current therapeutic approaches. Epilepsia 2013;54(Suppl 6):30-2
13. Marchi N, Granata T, Freri E, et al. Efficacy of anti-inflammatory therapy in a model of acute seizures and in a population of pediatric drug resistant epileptics. PLoS One 2011;6(3):e18200
14. Marchi N, Fan Q, Ghosh C, et al. Antagonism of peripheral inflammation reduces the severity of status epilepticus. Neurobiol Dis 2009;33(2):171-81
15. Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. Nat Rev Neurol 2011;7(1):31-40
16. Choi J, Nordli DR Jr, Alden TD, et al. Cellular injury and neuroinflammation in children with chronic intractable epilepsy. J Neuroinflammation 2009;6:38
17. Rüegg S. Autoimmunity and epilepsies in adults. Epileptologie 2014;31:4-25
18. Cacheaux LP, Ivens S, David Y, et al. Transcriptome profiling reveals TGF-beta signaling involvement in epileptogenesis. J Neurosci 2009;29(28):8927-35
19. van Vliet EA, da Costa Araujo S, Redeker S, et al. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 2007;130(Pt 2):521-34
20. Marchi N, Granata T, Alexopoulos A, Janigro D. The blood-brain barrier hypothesis in drug resistant epilepsy. Brain 2012;135(Pt 4):e211
21. Gilhus NE, Lea T. Carbamazepine: effect on IgG subclasses in epileptic patients. Epilepsia 1988;29(3):317-20
22. Pacifici R, Paris L, Di Carlo S, et al. Immunologic aspects of carbamazepine treatment in epileptic patients. Epilepsia 1991;32(1):122-7
23. Pacifici R, Zuccaro P, Iannetti P, et al. Immunologic aspects of vigabatrin treatment in epileptic children. Epilepsia 1995;36(4): 423-6
24. De Ponti F, Lecchini S, Cosentino M, et al. Immunological adverse effects of anticonvulsants. What is their clinical relevance? Drug Saf 1993;8(3):235-50
25. De Sarro GB, Berlinghieri MC, Elia M, et al. Does antiepileptic therapy affect immune response? J Chemother 1998;10(2): 184-6
26. Beghi E, Shorvon S. Antiepileptic drugs and the immune system. Epilepsia 2011; 52(Suppl 3):40-4
27. Ximenes JC, de Oliveira Goncalves D, Siqueira RM, et al. Valproic acid: an anticonvulsant drug with potent antinociceptive and anti-inflammatory properties. Naunyn Schmiedebergs Arch Pharmacol 2013;386(7):575-87
28. Zhang Z, Zhang ZY, Wu Y, Schluesener HJ. Valproic acid ameliorates inflammation in experimental autoimmune encephalomyelitis rats. Neuroscience 2012;221:140-50
29. Peng GS, Li G, Tzeng NS, et al. Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. Brain Res Mol Brain Res 2005; 134(1):162-9
30. Sinn DI, Kim SJ, Chu K, et al. Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation. Neurobiol Dis 2007;26(2): 464-72
31. Kim JE, Choi HC, Song HK, et al. Levetiracetam inhibits interleukin-1 beta inflammatory responses in the hippocampus and piriform cortex of epileptic rats. Neurosci Lett 2010;471(2):94-9
32. Dambach H, Hinkerohe D, Prochnow N, et al. Glia and epilepsy: experimental investigation of antiepileptic drugs in an astroglia/microglia co-culture model of inflammation. Epilepsia 2014;55(1):184-92
33. Verrotti A, Basciani F, Trotta D, et al. Effect of anticonvulsant drugs on interleukins-1,-2 and-6 and monocyte chemoattractant protein-1. Clin Exp Med 2001;1(3):133-6
34. Wei M, Li L, Meng R, et al. Suppressive effect of diazepam on IFN-gamma production by human T cells. Int Immunopharmacol 2010;10(3):267-71
35. Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 2011;134(Pt 10): 2802-18
36. Dale O, Somogyi AA, Li Y, et al. Does intraoperative ketamine attenuate inflammatory reactivity following surgery? A systematic review and meta-Analysis. Anesth Analg 2012;115(4):934-43
37. Loix S, De Kock M, Henin P. The anti-inflammatory effects of ketamine: state of the art. Acta Anaesthesiol Belg 2011; 62(1):47-58
38. De Kock M, Loix S, Lavand'homme P. Ketamine and peripheral inflammation. CNS Neurosci Ther 2013;19(6):403-10
39. Bien CG. Value of autoantibodies for prediction of treatment response in patients with autoimmune epilepsy: review of the literature and suggestions for clinical management. Epilepsia 2013;54(Suppl 2): 48-55
40. Viaccoz A, Laive P. Autoimmune epilepsie: treatment overview. Epileptologie 2014;31: 32-7
41. Ghawche F, Bordet R, Destee A. [Hashimoto's encephalopathy: toxic or autoimmune mechanism?]. Rev Neurol (Paris) 1992;148(5):371-3
42. Bostantjopoulou S, Zafiriou D, Katsarou Z, Kazis A. Hashimoto's encephalopathy: clinical and laboratory findings. Funct Neurol 1996;11(5):247-51
43. Guillon B, de Ferron E, Feve JR, et al. Simple partial status epilepticus and antiglycolipid IgM antibodies: possible epilepsy of autoimmune origin. Arch Neurol 1997;54(10):1194-6
44. Olson JA, Olson DM, Sandborg C, et al. Type 1 diabetes mellitus and epilepsia partialis continua in a 6-year-old boy with elevated anti-GAD65 antibodies. Pediatrics 2002;109(3):E50
45. Tanaka Y, Nishida H, Yamada O, et al. [Intrathecal glutamate receptor antibodies in a patient with elderly-onset refractory epilepsy]. Rinsho Shinkeigaku 2003;43(6): 345-9
46. Duffey P, Yee S, Reid IN, Bridges LR. Hashimoto's encephalopathy: postmortem findings after fatal status epilepticus. Neurology 2003;61(8):1124-6
47. Jamrozik Z, Janik P, Kiljanski J, Kwiecinski H. [Hashimoto's encephalopathy. Case report and literature review]. Neurol Neurochir Pol 2004;38(1): 55-9
48. McKeon A, McNamara B, Sweeney B. Hashimoto's encephalopathy presenting with psychosis and generalized absence status. J Neurol 2004;251(8):1025-7
49. Arai M, Takahashi Y. [Subacute encephalitis with anti-glutamate receptor antibodies presented with epilepsia partialis continua]. Rinsho Shinkeigaku 2005;45(8):610-12
50. Ito T, Ooishi C, Chiba A, et al. [Limbic encephalitis associated with drug-induced hypersensitivity syndrome due to phenobarbital-A case report]. Rinsho Shinkeigaku 2005;45(7):495-501
51. Aydin-Ozemir Z, Tuzun E, Baykan B, et al. Autoimmune thyroid encephalopathy presenting with epilepsia partialis continua. Clin EEG Neurosci 2006;37(3):204-9
52. Wada Y, Takahashi R, Yanagihara C, et al. [Successful use of methylprednisolone therapy in a case of non-herpetic acute encephalitis with antibodies against ionotropic glutamate receptor epsilon2 and delta2]. Brain Nerve 2007;59(5):527-32
53. Harscher S, Rummler S, Oelzner P, et al. [Selective immunoadsorption in neurologic complications of systemic lupus erythematosus]. Nervenarzt 2007;78(4): 441-4
54. Tsai MH, Lee LH, Chen SD, et al. Complex partial status epilepticus as a manifestation of Hashimoto's encephalopathy. Seizure 2007;16(8):713-16
55. Kanter IC, Huttner HB, Staykov D, et al. Cyclophosphamide for anti-GAD antibodypositive refractory status epilepticus. Epilepsia 2008;49(5):914-20
56. Bayreuther C, Bourg V, Dellamonica J, et al. Complex partial status epilepticus revealing anti-NMDA receptor encephalitis. Epileptic Disord 2009;11(3):261-5
57. Sartori S, Martini G, Calderone M, et al. Severe epilepsy preceding by four months the onset of scleroderma en coup de sabre. Clin Exp Rheumatol 2009;27(3 Suppl 54): 64-7
58. Baglietto MG, Mancardi MM, Giannattasio A, et al. Epilepsia partialis continua in type 1 diabetes: evolution into epileptic encephalopathy with continuous spike-waves during slow sleep. Neurol Sci 2009;30(6):509-12
59. Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009;65(4):424-34
60. Kishi M, Sakakibara R, Ogata T, Ogawa E. Transient phonemic paraphasia by bilateral hippocampus lesion in a case of limbic encephalitis. Neurol Int 2010;2(1):e8
61. Irani SR, Bera K, Waters P, et al. Nmethyl-D-Aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010(Pt 6):1655-67
62. Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010;9(1):67-76
63. Pruss H, Dalmau J, Harms L, et al. Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. Neurology 2010;75(19):1735-9
64. Specchio N, Fusco L, Claps D, Vigevano F. Epileptic encephalopathy in children possibly related to immune-mediated pathogenesis. Brain Dev 2010;32(1):51-6
65. Nath U, Warren NM, Ali H. NMDA receptor encephalitis-expanding the clinical spectrum. BMJ Case Rep 2011;2011
66. Illingworth MA, Hanrahan D, Anderson CE, et al. Elevated VGKC-complex antibodies in a boy with fever-induced refractory epileptic encephalopathy in school-Age children (FIRES). Dev Med Child Neurol 2011; 53(11):1053-7
67. Lancaster E, Martinez-Hernandez E, Titulaer MJ, et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology 2011;77(18): 1698-701
68. Boronat A, Sabater L, Saiz A, et al. GABA (B) receptor antibodies in limbic encephalitis and anti-GAD-Associated neurologic disorders. Neurology 2011;76(9): 795-800
69. Lancaster E, Huijbers MG, Bar V, et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 2011;69(2):303-11
70. Suleiman J, Brenner T, Gill D, et al. VGKC antibodies in pediatric encephalitis presenting with status epilepticus. Neurology 2011;76(14):1252-5
71. Kramer U, Chi CS, Lin KL, et al. Febrile infection-related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children. Epilepsia 2011;52(11):1956-65
72. Holzer FJ, Rossetti AO, Heritier-Barras AC, et al. Antibody-mediated status epilepticus: a retrospective multicenter survey. Eur Neurol 2012;68(5):310-17
73. Ozkan M, Aksoy A, Cenesiz F, et al. The association of anti-glutamic acid decarboxylase antibodies with different neurological findings in childhood. Epilepsy Behav 2012;25(3):464-7
74. Lin JJ, Lin KL, Hsia SH, et al. Antiglutamic acid decarboxylase antibodies in children with encephalitis and status epilepticus. Pediatr Neurol 2012;47(4): 252-8
75. Motta E, Golba A, Kazibutowska Z, et al. [Anti-NMDA receptor encephalitis-case report]. Neurol Neurochir Pol 2012;46(3): 288-93
76. Steele SU, Cheah SM, Veerapandiyan A, et al. Electroencephalographic and seizure manifestations in two patients with folate receptor autoimmune antibody-mediated primary cerebral folate deficiency. Epilepsy Behav 2012;24(4):507-12
77. Quek AM, Britton JW, McKeon A, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol 2012;69(5):582-93
78. Lin JJ, Lin KL, Hsia SH, et al. VGKC complex antibodies in pediatric severe acute encephalitis: a study and literature review. Brain Dev 2013;35(7):630-5
79. Marques IB, Teotonio R, Cunha C, et al. Anti-NMDA receptor encephalitis presenting with total insomnia-A case report. J Neurol Sci 2014;336(1-2):276-80
80. Kumar G, Mittal S, Moudgil SS, et al. Histopathological evidence that hippocampal atrophy following status epilepticus is a result of neuronal necrosis. J Neurol Sci 2013;334(1-2):186-91
81. Monnerat BZ, Velasco TR, Nakano FN, et al. Opercular myoclonic-Anarthric status epilepticus due to glutamic acid decarboxylase antibody-Associated encephalitis. Epileptic Disord 2013;15(3): 342-6
82. Doe De Maindreville A, Gombert C, Thiriaux A, et al. [Hashimoto's encephalopathy: a rare cause of status epilepticus]. Rev Neurol (Paris) 2013; 169(4):345-9
83. Cikrikcili U, Ulusoy C, Turan S, et al. Non-convulsive status epilepticus associated with glutamic acid decarboxylase antibody. Clinical EEG Neurosci 2013;44(3):232-6
84. Li J, Saldivar C, Maganti RK. Plasma exchange in cryptogenic new onset refractory status epilepticus. Seizure 2013; 22(1):70-3
85. Gall CR, Jumma O, Mohanraj R. Five cases of new onset refractory status epilepticus (NORSE) syndrome: outcomes with early immunotherapy. Seizure 2013;22(3):217-20
86. Mameli C, Dilillo D, Spiri D, et al. Status epilepticus as manifestation of posterior reversible encephalopathy syndrome in a healthy child. Pediatr Neurol 2013;48(5): 418-20
87. Boronat A, Gelfand JM, Gresa-Arribas N, et al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol 2013;73(1):120-8
88. Sakakibara E, Takahashi Y, Murata Y, et al. Chronic periodic lateralised epileptic discharges and anti-N-methyl-D-Aspartate receptor antibodies. Epileptic Disord 2014; 16(2):218-22
89. Lee CH, Lin JJ, Lin KJ, et al. Caspr2 antibody limbic encephalitis is associated with Hashimoto thyroiditis and thymoma. J Neurol Sci 2014;341(1-2): 36-40
90. Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014;13(3):276-86
91. Toledano M, Britton JW, McKeon A, et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology 2014; 82(18):1578-86
92. Nabbout R. FIRES and IHHE: delineation of the syndromes. Epilepsia 2013; 54(Suppl 6):54-6
93. Nabbout R, Vezzani A, Dulac O, Chiron C. Acute encephalopathy with inflammation-mediated status epilepticus. Lancet Neurol 2011;10(1):99-108
94. Kramer U, Chi CS, Lin KL, et al. Febrile infection-related epilepsy syndrome (FIRES): does duration of anesthesia affect outcome? Epilepsia 2011;52(Suppl 8):28-30
95. Lin KL, Wang HS. Role of antineuronal antibodies in children with encephalopathy and febrile status epilepticus. Pediatr Neonatol 2014;55(3):161-7
96. Specchio N, Fusco L, Claps D, et al. Childhood refractory focal epilepsy following acute febrile encephalopathy. Eur J Neurol 2011;18(7):952-61
97. Milh M, Villeneuve N, Chapon F, et al. New onset refractory convulsive status epilepticus associated with serum neuropil auto-Antibodies in a school aged child. Brain Dev 2011;33(8):687-91
98. Nabbout R, Mazzuca M, Hubert P, et al. Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES). Epilepsia 2010;51(10):2033-7
99. Lin JJ, Lin KL, Hsia SH, et al. Therapeutic hypothermia for febrile infection-related epilepsy syndrome in two patients. Pediatr Neurol 2012;47(6):448-50
100. Cobo NH, Sankar R, Murata KK, et al. The ketogenic diet as broad-spectrum treatment for super-refractory pediatric status epilepticus: challenges in implementation in the pediatric and neonatal intensive care units. J Child Neurol 2014. [Epub ahead of print]
101. Maalouf M, Rho JM, Mattson MP. The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res Rev 2009;59(2):293-315
102. Ruskin DN, Kawamura M, Masino SA. Reduced pain and inflammation in juvenile and adult rats fed a ketogenic diet. PLoS One 2009;4(12):e8349
103. Yang X, Cheng B. Neuroprotective and anti-inflammatory activities of ketogenic diet on MPTP-induced neurotoxicity. J Mol Neurosci 2010;42(2):145-53
104. Polderman KH, Herold I. Therapeutic hypothermia and controlled normothermia in the intensive care unit: practical considerations, side effects, and cooling methods. Crit Care Med 2009;37(3): 1101-20
105. Li G, Bauer S, Nowak M, et al. Cytokines and epilepsy. Seizure 2011;20(3):249-56
106. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 2011;335(1):2-13
107. Duffy BA, Chun KP, Ma D, et al. Dexamethasone exacerbates cerebral edema and brain injury following lithium-pilocarpine induced status epilepticus. Neurobiol Dis 2014;63:229-36
108. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 2013;13(3):176-89
109. Winters JL. Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines. Hematology Am Soc Hematol Educ Program 2012;2012:7-12
110. Cortese I, Chaudhry V, So YT, et al. Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011; 76(3):294-300
111. Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice- evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010; 25(3):83-177
112. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006;6(5 Pt 1):859-66
113. Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Ann Rev Med 2008;59:237-50
114. Mok CC. Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther 2014;8:87-100
115. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12(2):157-65
116. Corry JJ, Dhar R, Murphy T, Diringer MN. Hypothermia for refractory status epilepticus. Neurocrit Care 2008;9(2):189-97
117. Thakur KT, Probasco JC, Hocker SE, et al. Ketogenic diet for adults in super-refractory status epilepticus. Neurology 2014;82(8): 665-70
118. Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain 2012; 135(Pt 8):2314-28
119. Buckley C, Oger J, Clover L, et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 2001;50(1):73-8